由 APOL1 高危变体 G1 和 G2 介导的肾病对血管紧张素转换酶抑制剂的敏感性不同。

IF 14.8 1区 医学 Q1 UROLOGY & NEPHROLOGY Kidney international Pub Date : 2024-12-01 Epub Date: 2024-08-23 DOI:10.1016/j.kint.2024.07.026
Esilida Sula Karreci, Sonako Jacas, Olivia Donovan, Diana Pintye, Nicholas Wiley, Zsuzsanna K Zsengeller, Johannes Schlondorff, Seth L Alper, David J Friedman, Martin R Pollak
{"title":"由 APOL1 高危变体 G1 和 G2 介导的肾病对血管紧张素转换酶抑制剂的敏感性不同。","authors":"Esilida Sula Karreci, Sonako Jacas, Olivia Donovan, Diana Pintye, Nicholas Wiley, Zsuzsanna K Zsengeller, Johannes Schlondorff, Seth L Alper, David J Friedman, Martin R Pollak","doi":"10.1016/j.kint.2024.07.026","DOIUrl":null,"url":null,"abstract":"<p><p>Apolipoprotein L1 (APOL1) variants G1 and G2 contribute to the excess risk of kidney disease in individuals of recent African ancestry. Since disease mechanisms and optimal treatments remain controversial, we study the effect of current standard-of-care drugs in mouse models of APOL1 kidney disease. Experiments were performed in APOL1 BAC-transgenic mice, which develop proteinuria and glomerulosclerosis following injection with a pCpG-free IFN-γ plasmid. Proteinuric, plasmid injected G1/G1 and G2/G2 mice were randomized to drug treatment or no treatment. Lisinopril, dapagliflozin, and hydralazine were administered in drinking water starting day seven. The urine albumin/creatinine ratio was measured twice weekly, and the kidneys examined histologically with the focal segmental glomerulosclerosis score computed from periodic acid-Shiff-stained sections. The angiotensin converting enzyme inhibitor lisinopril, at standard dose, reduced proteinuria by approximately 90-fold and reduced glomerulosclerosis in the APOL1 G1/G1 BAC-transgenic mice. These effects were independent of blood pressure. Dapagliflozin did not alter disease progression in either G1/G1 or G2/G2 mice. Proteinuria reduction and glomerulosclerosis in G2/G2 BAC-transgenic mice required lisinopril doses two times higher than were effective in G1/G1 mice but achieved a much smaller benefit. Therefore, in these BAC-transgenic mouse models of APOL1 disease, the anti-proteinuric and anti-glomerulosclerotic effects of standard dose lisinopril were markedly effective in G1/G1 compared with G2/G2 APOL1 mice. Comparable reduction in blood pressure by hydralazine treatment provided no such protection. Neither G1/G1 nor G2/G2 mice showed improvement with the sodium-glucose cotransporter-2 inhibition dapagliflozin. Thus, it remains to be determined if similar differences in ACE inhibitor responsiveness are observed in patients.</p>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":" ","pages":"1072-1085"},"PeriodicalIF":14.8000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2.\",\"authors\":\"Esilida Sula Karreci, Sonako Jacas, Olivia Donovan, Diana Pintye, Nicholas Wiley, Zsuzsanna K Zsengeller, Johannes Schlondorff, Seth L Alper, David J Friedman, Martin R Pollak\",\"doi\":\"10.1016/j.kint.2024.07.026\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Apolipoprotein L1 (APOL1) variants G1 and G2 contribute to the excess risk of kidney disease in individuals of recent African ancestry. Since disease mechanisms and optimal treatments remain controversial, we study the effect of current standard-of-care drugs in mouse models of APOL1 kidney disease. Experiments were performed in APOL1 BAC-transgenic mice, which develop proteinuria and glomerulosclerosis following injection with a pCpG-free IFN-γ plasmid. Proteinuric, plasmid injected G1/G1 and G2/G2 mice were randomized to drug treatment or no treatment. Lisinopril, dapagliflozin, and hydralazine were administered in drinking water starting day seven. The urine albumin/creatinine ratio was measured twice weekly, and the kidneys examined histologically with the focal segmental glomerulosclerosis score computed from periodic acid-Shiff-stained sections. The angiotensin converting enzyme inhibitor lisinopril, at standard dose, reduced proteinuria by approximately 90-fold and reduced glomerulosclerosis in the APOL1 G1/G1 BAC-transgenic mice. These effects were independent of blood pressure. Dapagliflozin did not alter disease progression in either G1/G1 or G2/G2 mice. Proteinuria reduction and glomerulosclerosis in G2/G2 BAC-transgenic mice required lisinopril doses two times higher than were effective in G1/G1 mice but achieved a much smaller benefit. Therefore, in these BAC-transgenic mouse models of APOL1 disease, the anti-proteinuric and anti-glomerulosclerotic effects of standard dose lisinopril were markedly effective in G1/G1 compared with G2/G2 APOL1 mice. Comparable reduction in blood pressure by hydralazine treatment provided no such protection. Neither G1/G1 nor G2/G2 mice showed improvement with the sodium-glucose cotransporter-2 inhibition dapagliflozin. Thus, it remains to be determined if similar differences in ACE inhibitor responsiveness are observed in patients.</p>\",\"PeriodicalId\":17801,\"journal\":{\"name\":\"Kidney international\",\"volume\":\" \",\"pages\":\"1072-1085\"},\"PeriodicalIF\":14.8000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kidney international\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.kint.2024.07.026\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney international","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.kint.2024.07.026","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

载脂蛋白 L1(APOL1)变体 G1 和 G2 会导致非洲裔个体罹患肾病的风险过高。由于疾病机制和最佳治疗方法仍存在争议,我们在 APOL1 肾病小鼠模型中研究了目前标准治疗药物的效果。实验在 APOL1 BAC 转基因小鼠中进行,这些小鼠在注射不含 pCpG 的 IFNɤ 质粒后出现蛋白尿和肾小球硬化。对注射了质粒的蛋白尿 G1/G1 和 G2/G2 小鼠随机进行药物治疗或不治疗。从第七天开始,利辛普利、达帕利嗪和水蛭素在饮用水中给药。每周测量两次尿白蛋白/肌酐比值,并对肾脏进行组织学检查,根据周期性酸-希夫染色切片计算局灶节段性肾小球硬化评分。标准剂量的血管紧张素转换酶抑制剂利辛普利可使 APOL1 G1/G1 BAC 转基因小鼠的蛋白尿减少约 90 倍,并减轻肾小球硬化。这些效果与血压无关。达帕格列净并未改变 G1/G1 或 G2/G2 小鼠的疾病进展。减少 G2/G2 BAC 转基因小鼠的蛋白尿和肾小球硬化所需的利辛普利剂量是对 G1/G1 小鼠有效剂量的两倍,但获得的益处却小得多。因此,在这些 BAC 转基因小鼠 APOL1 疾病模型中,与 G2/G2 APOL1 小鼠相比,标准剂量的利辛普利对 G1/G1 小鼠的抗蛋白尿和抗肾小球硬化效果显著。而通过肼屈嗪治疗降低血压并不能提供这种保护。钠-葡萄糖共转运体-2抑制剂达帕格列净对G1/G1或G2/G2小鼠均无改善。因此,患者对 ACE 抑制剂的反应是否存在类似差异仍有待确定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2.

Apolipoprotein L1 (APOL1) variants G1 and G2 contribute to the excess risk of kidney disease in individuals of recent African ancestry. Since disease mechanisms and optimal treatments remain controversial, we study the effect of current standard-of-care drugs in mouse models of APOL1 kidney disease. Experiments were performed in APOL1 BAC-transgenic mice, which develop proteinuria and glomerulosclerosis following injection with a pCpG-free IFN-γ plasmid. Proteinuric, plasmid injected G1/G1 and G2/G2 mice were randomized to drug treatment or no treatment. Lisinopril, dapagliflozin, and hydralazine were administered in drinking water starting day seven. The urine albumin/creatinine ratio was measured twice weekly, and the kidneys examined histologically with the focal segmental glomerulosclerosis score computed from periodic acid-Shiff-stained sections. The angiotensin converting enzyme inhibitor lisinopril, at standard dose, reduced proteinuria by approximately 90-fold and reduced glomerulosclerosis in the APOL1 G1/G1 BAC-transgenic mice. These effects were independent of blood pressure. Dapagliflozin did not alter disease progression in either G1/G1 or G2/G2 mice. Proteinuria reduction and glomerulosclerosis in G2/G2 BAC-transgenic mice required lisinopril doses two times higher than were effective in G1/G1 mice but achieved a much smaller benefit. Therefore, in these BAC-transgenic mouse models of APOL1 disease, the anti-proteinuric and anti-glomerulosclerotic effects of standard dose lisinopril were markedly effective in G1/G1 compared with G2/G2 APOL1 mice. Comparable reduction in blood pressure by hydralazine treatment provided no such protection. Neither G1/G1 nor G2/G2 mice showed improvement with the sodium-glucose cotransporter-2 inhibition dapagliflozin. Thus, it remains to be determined if similar differences in ACE inhibitor responsiveness are observed in patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Kidney international
Kidney international 医学-泌尿学与肾脏学
CiteScore
23.30
自引率
3.10%
发文量
490
审稿时长
3-6 weeks
期刊介绍: Kidney International (KI), the official journal of the International Society of Nephrology, is led by Dr. Pierre Ronco (Paris, France) and stands as one of nephrology's most cited and esteemed publications worldwide. KI provides exceptional benefits for both readers and authors, featuring highly cited original articles, focused reviews, cutting-edge imaging techniques, and lively discussions on controversial topics. The journal is dedicated to kidney research, serving researchers, clinical investigators, and practicing nephrologists.
期刊最新文献
Allocation biopsies of deceased donor kidneys: a necessary tool to expand the donor pool. Biopsy before transplant: optimizing allocation or fueling discard? Chylothorax and chylopericardium in a dialysis patient. Corrigendum to "CD248 induces a maladaptive unfolded protein response in diabetic kidney disease." Kidney International 2023;103:304-319. Corrigendum to "Long-term impact of immediate versus deferred antiretroviral therapy on kidney health in people with HIV." Kidney International 2024;106:136-144.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1